Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery

Cell Rep. 2019 Feb 5;26(6):1399-1408.e6. doi: 10.1016/j.celrep.2019.01.047.

Abstract

Bariatric surgery is widely used to treat obesity and improves type 2 diabetes beyond expectations from the degree of weight loss. Elevated post-prandial concentrations of glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and insulin are widely reported, but the importance of GLP-1 in post-bariatric physiology remains debated. Here, we show that GLP-1 is a major driver of insulin secretion after bariatric surgery, as demonstrated by blocking GLP-1 receptors (GLP1Rs) post-gastrectomy in lean humans using Exendin-9 or in mice using an anti-GLP1R antibody. Transcriptomics and peptidomics analyses revealed that human and mouse enteroendocrine cells were unaltered post-surgery; instead, we found that elevated plasma GLP-1 and PYY correlated with increased nutrient delivery to the distal gut in mice. We conclude that increased GLP-1 secretion after bariatric surgery arises from rapid nutrient delivery to the distal gut and is a key driver of enhanced insulin secretion.

Keywords: GLP-1; bariatric surgery; enteroendocrine cells; gut hormones; intestinal transit; mass spectrometry; peptidomics; transcriptomics.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Bariatric Surgery*
  • Enteroendocrine Cells / metabolism
  • Female
  • Glucagon-Like Peptide 1 / blood
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucose / metabolism*
  • Homeostasis*
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Insulin Secretion
  • Intestinal Mucosa / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Obesity / drug therapy
  • Obesity / metabolism*
  • Obesity / surgery
  • Peptide Fragments / adverse effects
  • Peptide Fragments / therapeutic use
  • Peptide YY / metabolism
  • Postoperative Period
  • Transcriptome

Substances

  • Hypoglycemic Agents
  • Peptide Fragments
  • Peptide YY
  • exendin (9-39)
  • Glucagon-Like Peptide 1
  • Glucose